GlaxoSmithKline

• 

  Pharma Patent Ruling Pinches Opportunities in Emerging Markets

  By Marlene Y. Satter, AdvisorOne  |  May 9, 2013

  The decision by an Indian court not to grant a new patent to Novartis for a modified form of its cancer drug Glivec was a heavy blow to the company.

• 

  Top 30 401(k) Plans of 2012

  By Ron Pechtimaldjian, AdvisorOne  |  December 12, 2012

  Brightscope, which provides retirement plan ratings and investment research, released its fourth annual Top 30 401(k) plans with more than $1 billion in assets.

• Biotech/Health Care Investing: Selective Growth

  By Janet Levaux, AdvisorOne  |  March 1, 2009

  --- Alexandra Hauber J.P. Morgan 312-325-3694 Alexandra.m.hauber@jpmorgan.com We expect currency to have a significant impact on 2009 earnings. The biggest effect, due to the British pound weakness, is likely at...

• Aussie boomers binge on booze

  By Staff Writer  |  September 1, 2008

  Australian baby boomers are out-drinking their teenage children, with figures revealing parents are drinking more than 20 drinks a week. Okay, but c'mon, this is...

• Positive Outlook

  By Staff Writer  |  March 1, 2007

  Companies in a variety of biotech and health-care sectors should see sales and development progress in 2007, analysts say. Edward A. Tenthoff Piper Jaffray & Co. 212-284-9403 edward.a.tenthoff@pjc.com Area of...

• Buying The Future

  By Staff Writer  |  December 1, 2005

  If you were to suggest to colleagues or clients that the biotechnology sector presents a good opportunity for investment, they might very well respond with...